Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2Phase 2 1

Status

Terminated 3Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 123Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 84Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 42Myelodysplastic Syndromes 41Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Triple Negative Breast Neoplasms 33Carcinoma, Hepatocellular 33Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

tildrakizumab 1sabizabulin 1enzalutamide 1N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Metastatic Castration Resistant Prostate Cancer × Clear all
NCT03177187 2024-09-26

ACE

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
30 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
13 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03752099 2023-09-26

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Veru Inc.

Phase 1/2 Terminated
80 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡